eMed

Today eMed is focused on access to GLP-1/GIP medications through employer benefit programs to address the chronic condition of obesity. Over 40% of adults live with obesity in the United States and eMed’s Population Health GLP-1/GIP program empowers employees to achieve their health goals and employers to reduce baseline program costs by up to 50%. Leveraging eMed Empathetic AI™ technology and a seamless digital experience, eMed’s platform provides employers auditable ROI through cost avoidance and improved population health. eMed guarantees participant adherence, reduces costly ancillary medical services, and lowers medication spend, while providing instant access to live care with no appointments ever.